Technology Commercialization Office

Showing 61 result(s) for "Life Sciences"



The SMN2 gene contains sequences that regulate the level of inclusion of SMN exon7 in SMN mRNA, and some of these act in a negative manner. Antisense oligonucleotides to block the negative regulating protein binding to these sites can increase inclusion of SMN exon 7 and thus, the amount of SMN being produced.

A treatment for spinal muscular atrophy.

A novel plasmid addiction system for cost-effective end-product generation.

A novel method using the overexpression of survival motor neuron protein to improve motor unity synaptic repair and restore/protect muscle size and function due to sarcopenia.

Inh2-B1 serves as a therapeutically important “antibiotic-resistance-breaker,” which enhances the bactericidal activity of Ceftriaxone/Cefotaxime against highly pathogenic MDRSA infection.

A combination-therapy that has the potential to overcome and/or prevent the commonly observed acquisition of sorafenib resistance, which is associated with treatment failure in patients with hepatocellular carcinoma.

A method of evenly distributing beneficial mites throughout a greenhouse using a novel device.

A specific and rapidly reversible system for single molecule capture employing magnesium-dependent DNA quadruplex structures.

An enhanced nucleic acid amplification system that is more efficient and cost-effective than conventional polymerase chain reaction methods.

An efficient delivery vehicle for therapeutic oligonucleotides with high efficiency.